London-listedtold investors on Friday that its portfolio company, Exscientia, had entered into a collaboration deal worth up to £203 million with global pharmaceutical giant Bayer to leverage AI in drug discovery.
Specifically, the collaboration will aim to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology, the statement detailed.
Under the terms of the deal, Exscientia, of which Frontier owns a 3.25% stake in, will initially work on three projects applying its Centaur Chemist™platform which uses AI to identify new drugs.
The group is eligible to receive up to €240 Million including upfront, research and clinical milestone payments as well as possible sales royalties.
Shares in Frontier IP Group were trading 4.51% higher at 69.5p on Friday midday.
“Since our pioneering Nature papers demonstrating the automated design of small-molecules, we have enhanced our platform and exemplified it commercially,” said Professor Andrew Hopkins, CEO of Exscientia.
Dr. Joerg Moeller of Bayer AG’s pharmaceutical division and Head of R&D emphasised the value in progressing technologies which can “simplify and speed up the discovery and development of new drugs for patients.”
“The collaboration with Exscientia is expected to help us to achieve project milestones earlier and at the same time accelerate timelines by enabling more precise identification of suitable drug targets and lead structures,” he added.
Follow News & Updates from Frontier IP Group here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
SP Angel research note on commodities and miners, featuring: Rio Tinto (RIO LN) – Q4 and 2019 production results highlight “value over volume” Sibanye-Stillwater - cuts close to 1,142 jobs at the Marikana platinum mines despite record palladium prices
The news follows two initial orders made by the group’s Nigerian distribution partner for a combined total of 250,000 tests in December which Omega said at the time remained conditional upon MOH’s approval of the test into Nigeria’s national HIV policy.
The London-listed group said this would put in place a framework of cooperation between itself and the CREHK-CRWE Joint Venture regarding future projects where they may work together.
“The process to finalise a tariff offer for submission to EDM is well underway and on track for submission in Q1 2020,” said Chief Executive, Hanno Pengilly, commenting on the power project which epitomises one of the fastest growing sectors in Africa today.
Paul Duffen, Executive Chairman of the Company, commented: "Having 100% ownership of Bet90 represents significant progress towards our stated objective to refocus the business on the core activity of online sportsbook and casino operations.”